About Bryan Wheelock

Education J.D., Washington University in St. Louis B.S.E. in Mechanical Engineering, Duke University Bryan Wheelock's practice includes preparation and prosecution of patent and trademark applications and drafting of intellectual property agreements, including non-compete agreements. He has brought and defended lawsuits in federal and state courts relating to intellectual property and has participated in seizures of counterfeit and infringing goods. Bryan prepares and prosecutes U.S. and foreign patent applications for medical devices, mechanical and electromechanical devices, manufacturing machinery and processes, metal alloys and other materials. He also does a substantial amount of patentability searching, trademark availability searching and patent and trademark infringement studies. In addition to his practice at Harness Dickey, Bryan is an Adjunct Professor at Washington University School of Law and Washington University School of Engineering.

August 6, 2014

New Filings

Ericsson Inc. filed IPR2014-01170 challenging U.S. Patent No. 7,385,994, assigned to Intellectual Ventures II LLC.

Veeva Systems Inc. filed IPR2014-01253 challenging U.S. Patent No. 7,634,556, assigned to Silicon Valley Bank.

Institution Decisions

In Monosol RX, LLC v. Arius Two, Inc., IPR2014-00376, Paper 11 (August 6, 2014), the Board instittued inter partes review of claims 1-7 of U.S. Patent No. 7,579,019.

In Motorola Mobility LLC v. Intellectual Ventures I LLC, CBM2014-00083, Paper 17 (August 6, 2014), the Board denied covered business method review of claims 151, 159, 161, 162, 181, 189, 191, 192, 256, 264, 266, and 267 of U.S. Patent No. 6,577,054.

In Motorola Mobility LLC v. Intellectual Ventures I LLC, CBM2014-00084, Paper 18 (August 6, 2014), the Board denied covered business method review of claims 1, 8, 16, and 17 of U.S. Patent No. 6,658,464.

In Ericsson, Inc. v. Intellectual Ventures I LLC, IPR2014-00257, Paper  11 (August 6, 2014), the Board instituted inter partes review of claims 1–22 of U.S. Patent No. 7,496,674.

Dispositions

In SAS Institute Inc. v. Complementsoft, LLC, IPR2013-00226, Paper 38, (August 6, 2014), the Board issued a final written decision finding that claims 1, 3, and 5-10 of U.S. Patent No. 7,110,936 are unpatentable, but not challenged claim 4.

In Hewlett-Packard Company v. MCM Portfolio LLC, IPR2013-00227, Paper 31 (August 6, 2014), the Board issued a final written decision finding that claims 7, 11, 19, and 21 of U.S. Patent No. 7,162,549 (all of the challenged claims) are unpatentable.

In Pharmatech Solutions, Inc. v. LifeScan Scotland Ltd., IPR2013-00247, Paper 27 (August 6, 2014), the Board found that claims 1-3 (the “challenged claims”) of U.S. Patent No. 7,250,105 were unpatentable.

Decisions on Rehearing

In Purdue Pharma L.P. v. Depomed, Inc., IPR2014-00377, Paper 17  IPR2014-00378, Paper 18 (August 6, 2014), the Board denied Petitioner’s request for rehearing of the denial of inter partes review.

In Symantec Corporation v. RPOST Communications Limited, IPR2014-00357, Paper 18 (August 6, 2015), the Board denied petitioner’s request for rehearing of its institution decision.

 

 

First Post Grant Review Filed August, 5, 2014

On August 5, 2014, LaRose Industries, LLC filed PGR2014-000008, challenging the validity of U.S. Patent No. 8,684,420, assigned to Choon’s Design Inc., which issued on April 1, 2014, on an application filed on July 26, 2013.  In addition to 102 and 103 grounds, which could have been brought in an inter partes review (but not until January 2015), the Petition alleged invalidity under 35 USC 112 for lack of written description, indefiniteness, and lack of enablement.

More Details, Details

Samsung Electronics Co., Ltd. v. Affinity Labs of Texas, IPR2014-01184, Paper 3, IPR2014-01182, Paper 3, IPR2014-01181, Paper 3, August 5, 2014), the Board granted the Petition a filing date, but gave the petitioner five business days to correct the claim charts. The Board cautioned:

Claim charts should only be used to provide an element-by-element showing as to how the prior art teaches the limitations of a claim (e.g., citations to a prior art reference, quotations from a prior art reference). Claim charts may not include arguments, claim construction, statements of the law, or detailed explanations as to why a claim limitation is taught or rendered obvious by the prior art. A mere citation to an expert declaration (e.g., “See Ex. 1015 ¶ 29”) in a claim chart is permissible, but anything more than a mere citation is improper.

Footnotes are part of the claim charts and arguments should not be included.

 

August 5, 2014

Dispositions

In Heartland Tanning, Inc. v. MT Manufacturing, Inc., IPR2014-00018, Paper 30 (August 5, 2014), the Board granted the parties joint motion to terminate the proceedings based on settlement.

August 4, 2014

New Filings

Ericcson Inc. filed IPR2014-01149 challenging U.S. Patent No. 6,023,783, assigned to Intellectual Ventures I LLC.

Johnson Health Tech Co., Ltd, filed IPR2014-01242 challenging U.S. Patent No. 6,193,631 asigned to Wilmington Trust FSB.

Geox S.p.A. filed IPR2014-01244 challenging U.S. Patent No. 6,855,171 assigned to Columbia Sportswear Company.

Wintek Corporation filed IPR2014-01245 challenging U.S. Patent No. 8,283,935 assigned to TPK TOUCH SOLUTIONS INC.

Mercedes-Benz USA, LLC filed IPR2014-01247 challenging U.S. Patent No. 5,954,781 assigned to Velocity Patents LLC.

Tietex International, Ltd. filed IPR2014-01248 challenging U.S. Patent No. 8,501,639.

HTC Corporation filed IPR2014-01249 challenging U.S. Patent No. 6,362,850, assigned to Flashpoint Technology, Inc.

Institution Decisions

In Schrader International, Inc. v. Wasica Gmbh, IPR2014-00476, Paper 7 (August 2014), instituted inter partes review of claims 1-6, 9-10, 12-19, and 21 (but not claim 11) of U.S. Patent No. 5,602,524.

Dispositions

In Impax Laboratories, Inc. v. Meda Pharmaceuticals Inc., IPR2014-00731, Paper 12 (August 4, 2014), the Board granted the parties’ joint motion to terminate,

August 1, 2014

New FIlings

Vonage Holdings Corporation filed IPR2014-01223 challenging U.S. Patent No 6,513,066, assigned to Straight Path IP Group, Inc.

NetApp filed IPR2014-01233 challenging U.S. Patent No. 7,987,311, assigned to Crossroads Systems, Inc.

Claim Amendment Remains Possible but Unlikely

In Greene’s Energy Group, LLC v. Oil States Energy Services, L.L.C., IPR2014-0261, Paper 18 (August 15, 2014), the Board’s advice to a patent own on preparing a motion to amend is a reminder to the rest of us, that amending claims in a IPR is virtuall impossible.  The amendment must “respond to a ground of unpatentability involved in the trial” and it cannot ” enlarge the scope of the claims of the patent or introduce new subject matter.”  Furthermore amendment is not authorized unless the movant shows that theclaims are patentable.  In the 15 pages allowed, the patent owner must:

identify specifically the feature(s) or limitation(s) added to each substitute claim, as compared to the challenged claim it replaces, and come forward with technical facts and reasoning about those feature(s) or limitation(s), including the construction of new claim terms, sufficient to persuade the Board that the proposed substitute claim is patentable over the prior art of record, and over prior art not of record, but known to Patent Owner.

A mere conclusory statement by counsel in the motion to amend that one or more added features or limitations are not described in any prior art or would not have been suggested or rendered obvious by the prior art is facially inadequate. It also is insufficient for the movant simply to explain why the proposed substitute claims are patentable in consideration of the challenges on which the Board instituted review. Limiting the discussion either to the references already in the proceeding, or to the narrow combination specifically recited in the claim, does not provide a meaningful analysis.

In these 15 pages the patent owner also must clearly identify the written description support for the proposed substitute claims. Merely indicating where each claim limitation individually is described in the original disclosure may be insufficient to demonstrate support for the claimed subject matter as a whole.

There is nothing new here — amendment during inter partes review remains out of reach for most patent owners.

.

 

 

 

July 29, 2014

New Filings

Gordon * Howard Associates, Inc., filed IPR2014-01213 challenging U.S. Patent No. 6,484,035, assigned to Lunareye, Inc.

EMC Corporation filed UPR2014-01216 challenging U.S. Patent No. 5,825,891 assigned to STEC IP, LLC.

EMC Corporation filed UPR2014-01217 challenging U.S. Patent No. 6,925,481 assigned to Reefedge, Inc.

EMC Corporation filed UPR2014-01218 challenging U.S. Patent No. 7,254,621assigned to STEC IP, LLC.

Institution Decisions

In BioDelivery Sciences International, Inc. v. RB Pharmaceuticals Limited, IPR2014-00325, Paper 17 (July 29, 2014), the Board instituted inter partes review of claims 15-19 of U.S. Patent No. 8,475,832

Terminations

In RF Micro Devices, Incorporated v. Peregrine Semiconductor Corporation, IPR2014-00546 (July 29, 2014), the Board terminated the inter partes review on the joint motion of the parties

 

\

Discovery Remains Hard To Get

In Electronic Frontier Foundation v. James D. Logan, IPR2014-00070, Paper 32 (July 29, 2014), the Board denied pettioner’s motion to compel discovery relating to the on-going litigation involving the patent, to uncover inconsistent positions of the patent owner.  The Board said it required more than speculation that an inconsistency exists to require production under 37 C.F.R. § 42.51(b)(1)(iii).  The Board instructed the parties to confer about the requests, and authorized the petitioner to contact the Board if an agreement cannot be reached,